Home / Business and Economy / Zepbound's Real-World Data Boosts Insurance Hopes
Zepbound's Real-World Data Boosts Insurance Hopes
2 Sep
Summary
- Zepbound may reduce healthcare costs by up to 38% in a year.
- A study showed lower hospital admissions for Zepbound users.
- Eli Lilly's Q2 revenue surged 48% to $23 billion.
Eli Lilly is pursuing expanded insurance coverage for its weight-loss medication, Zepbound. Recent real-world study results suggest Zepbound may lead to significant healthcare cost reductions for patients.
The study found that patients over 55 using Zepbound experienced up to 38% lower healthcare costs after one year, including fewer hospital admissions and emergency visits compared to a control group. These findings could persuade health insurance companies to cover the drug, potentially increasing its accessibility and demand.
While the study did not factor in Zepbound's own cost, it provides crucial data for Eli Lilly's negotiations with payers. Expanded coverage could significantly boost sales, especially as many patients currently pay out-of-pocket or opt for less expensive compounded versions.
Beyond Zepbound, Eli Lilly reported a 48% year-over-year revenue increase to $23 billion in the second quarter. Mounjaro sales reached $9.9 billion, and Zepbound generated $4.9 billion. The company maintains a strong market position in weight loss and diabetes, with a diverse portfolio and promising pipeline candidates across various therapeutic areas.
